Berdagang Vir Biotechnology VIR

Jual
 Beli

VirBiotechnology carta live

5m 15m 30m 1h 4h 1d 1w

Asas Instrumen

Weekly Search
Weekly
Daily
Tarikh Tutup Perubahan Perubahan (%): Buka Tinggi Rendah

VirBiotechnology news

Berita Terkini

Tunjukkan lebih lagi
Liam James 2025 Aug 22, 15:20

Market Review & Investment Insights: August 2025

Noah Lee 2025 Aug 22, 15:20

Trump Threatens to Fire Fed Governor Lisa Cook Amid Mortgage Fraud Allegations

Liam James 2025 Aug 22, 15:20

Wall Street Reacts: Powell Hints at September Rate Cut, But Cautiously

Liam James 2025 Aug 22, 14:20

Dollar Bullish Sentiment Rises Ahead of Powell Speech, Forex Options Show

Ava Grace 2025 Aug 22, 12:20

Syria to Revalue Currency: Removing Zeros in Bid to Restore Confidence

Noah Lee 2025 Aug 22, 10:20

India, Russia Expand Trade Amid US Tariff Pressure

Ava Grace 2025 Aug 22, 08:20

Trump Administration Eyes Repurposing Chip Act Funds for Critical Minerals

Emma Rose 2025 Aug 22, 08:20

Powell's Jackson Hole Speech: Shaping the Fed's Future Amidst Economic Uncertainty

Maklumat

Sebaran nilai

0.03

Spread (%)

0.6565 %

Leveraj

1:10

Faedah semalaman (Beli)

-0.0597 %

Faedah semalaman (Jual)

-0.0292 %

Mata wang

USD

Waktu perdagangan

Pasaran ditutup

Isnin

13:31 - 19:59

Selasa

13:31-19:59

Rabu

13:31-19:59

Khamis

13:31-19:59

Jumaat

13:31-19:59

Analisis dan statistik

Buka

---

Tutup Terdahulu

---

Tinggi/Rendah 52 Minggu

--- – ---

Modal pasaran

608452096

Saham Tertunggak

138916000

Tarikh Pendapatan (Seterusnya)

0000-00-00

Hasil Div

Tarikh Selepas Dividen

Kadar dividen tahunan depan

0

Hasil dividen tahunan depan

0

EPS

-4.01

Ketahui lebih lanjut mengenai instrumen ini

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Instrumen Berkaitan

Aset
Jual
Beli
Perubahan (%):

Berdaganglah Sekarang

Berdaganglah Sekarang

Berdaganglah Sekarang

Berdaganglah Sekarang
Instrumen Berkaitan

latest_education_articles

Tunjukkan lebih lagi
Trustpilot